Get the Stockscreener App
79.23
0.45%
-0.08
Bright Minds Biosciences Inc stock is traded at $79.23, with a volume of 52,504.
It is down -0.45% in the last 24 hours and up +8.03% over the past month.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$79.31
Open:
$79.31
24h Volume:
52,504
Relative Volume:
0.31
Market Cap:
$775.63M
Revenue:
-
Net Income/Loss:
$-4.98M
P/E Ratio:
-60.13
EPS:
-1.3177
Net Cash Flow:
$-3.85M
1W Performance:
-7.66%
1M Performance:
+8.03%
6M Performance:
+86.91%
1Y Performance:
+119.37%
1-Day Range:
$78.91
$80.50
1-Week Range:
$78.58
$86.12
52-Week Range:
$23.18
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
79.25 | 776.22M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.00 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.24 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.48 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
293.38 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | BTIG Research | Buy |
| May-13-25 | Initiated | TD Cowen | Buy |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
View All
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Bright Minds stock price target raised to $145 by H.C. Wainwright on trial data - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
DRUG: HC Wainwright & Co. Raises Price Target to $145, Maintains Buy Rating | DRUG Stock News - GuruFocus
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Precision Trading with Bright Minds Biosciences Inc. (DRUG) Risk Zones - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
DRUG Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bright Minds Biosciences to Present at Upcoming Conferences - Bitget
Published on: 2026-02-24 23:01:51 - baoquankhu1.vn
Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap UpWhat's Next? - MarketBeat
Stock Report: What are Bright Minds Biosciences Incs recent SEC filings showingJuly 2025 Chart Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Baird lowers Bright Minds Biosciences Inc. (DRUG) price target to $126, maintains outperform rating ahead of upcoming trials - MSN
Technical Reactions to DRUG Trends in Macro Strategies - Stock Traders Daily
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials - Finviz
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Up 7.9%Here's What Happened - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from BTIG Research - MarketBeat
Will Bright Minds Biosciences Inc. benefit from rate cutsWeekly Trading Summary & AI Based Trade Execution Alerts - mfd.ru
7 Most Promising Psychedelic Stocks According to Hedge Funds - Insider Monkey
What are Bright Minds Biosciences Inc.’s recent SEC filings showingRate Cut & Weekly Top Gainers Trade List - mfd.ru
Wall Street Zen Upgrades Bright Minds Biosciences (NASDAQ:DRUG) to Hold - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Down 6.2%Time to Sell? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Issues Earnings Results, Beats Estimates By $0.28 EPS - MarketBeat
Bright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D Loss - TipRanks
Is Bright Minds Biosciences Inc. stock dividend yield sustainableJuly 2025 Trends & Free Community Supported Trade Ideas - mfd.ru
Will Bright Minds Biosciences Inc. benefit from rising consumer demandQuarterly Growth Report & Fast Moving Stock Watchlists - mfd.ru
Trading the Move, Not the Narrative: (DRUG) Edition - Stock Traders Daily
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Bright Minds Biosciences (DRUG) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Rally Mode: Is Bright Minds Biosciences Inc undervalued by DCF analysisJuly 2025 Technicals & AI Powered Market Entry Ideas - baoquankhu1.vn
Dow Update: Will Bright Minds Biosciences Inc. benefit from AI trendsWeekly Profit Recap & High Yield Equity Trading Tips - baoquankhu1.vn
How interest rate cuts could boost Bright Minds Biosciences Inc. stockJuly 2025 Sector Moves & Weekly Setup with ROI Potential - mfd.ru
Short Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Rises By 67.5% - MarketBeat
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet - MSN
What are the risks of holding Olin CorporationJuly 2025 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Several Bright Minds Biosciences Insiders Sell Shares Sending Potential Negative Signal - simplywall.st
Aug Big Picture: Is SSNC stock trending bullishJuly 2025 Big Picture & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
(DRUG) Volatility Zones as Tactical Triggers - Stock Traders Daily
Price-Driven Insight from (DRUG) for Rule-Based Strategy - Stock Traders Daily
Bright Minds reports positive Phase 2 results for epilepsy drug By Investing.com - Investing.com Nigeria
New epilepsy study tests drug for adults whose seizures resist treatment - Stock Titan
Volume Summary: How Bright Minds Biosciences Inc. stock performs in high volatility markets - Bộ Nội Vụ
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Bright Minds Biosciences Stock Topped the Market on Monday - MSN
Bright Minds Biosciences closes $175 million public offering By Investing.com - Investing.com Nigeria
Warm welcome for Aktis could open up IPO queue: Public Equity Report - BioCentury
Bright Minds Biosciences (NASDAQ:DRUG) Cut to "Sell" at Wall Street Zen - MarketBeat
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline - TipRanks
Bright Minds prices $175M stock offering - MSN
Bright Minds Biosciences Reports Phase 2 BMB-101 Data: 73% Median Drop in Absence Seizures on EEG - MarketBeat
Bright Minds Biosciences Closes its US$175 Million Public Offering - marketscreener.com
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):